TRAIL negatively regulates VEGF-induced angiogenesis via caspase-8-mediated enzymatic and non-enzymatic functions

Angiogenesis

Volumn 17, Issue 1, 2014, Pages 179-194

  Na, Hee Jun ^a   Hwang, Jong Yun ^b   Lee, Kwang Soon ^a   Choi, Yoon Kyung ^a   Choe, Jongseon ^a   Kim, Ji Yoon ^c   Moon, Hyo Eun ^d   Kim, Kyu Won ^d   Koh, Gou Young ^e   Lee, Hansoo ^a   Jeoung, Dooil ^a   Won, Moo Ho ^a   Ha, Kwon Soo ^a   Kwon, Young Guen ^f   Kim, Young Myeong ^a  

^a Kangwon National University   (South Korea)

^b Kangwon National University College of Medicine   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d Seoul National University   (South Korea)

^e Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^f Yonsei University   (South Korea)

Author keywords

Angiogenesis; Caspase 8; Endothelial cells; TRAIL; VEGF

Indexed keywords

ACTIN; CASPASE 3; CASPASE 8; CASPASE 9; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FAK PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PAXILLIN; PROTEIN KINASE B; SRC PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CHICKEN; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CASPASE 8; CHICK EMBRYO; HELA CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84892765114     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-013-9387-0     Document Type: Article

References (55)

1. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM (1997) The receptor for the cytotoxic ligand TRAIL. Science 276:111-113
2. Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A (2009) TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 35:280-288
3. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821
4. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277:815-818
5. Di Pietro R, Zauli G (2004) Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 201:331-340
6. Thorburn A, Behbakht K, Ford H (2008) TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat 11:17-24
7. Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B (2009) Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Mol Cancer Res 7:1835-1844
8. Ebos JM, Kerbel RS (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8:210-2121
9. Folkman J (2001) Angiogenesis-dependent diseases. Semin Oncol 28:536-542
10. Rapisarda A, Melillo G (2012) Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res 114:237-267
11. Prokopiou EM, Ryder SA, Walsh JJ (2013) Tumour vasculature targeting agents in hybrid/conjugate drugs. Angiogenesis 16:503-524
12. Nitzsche B, Gloesenkamp C, Schrader M, Hoffmann B, Zengerling F, Balabanov S, Honecker F, Höpfner M (2012) Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. Br J Cancer 107:1853-1863
13. Idbaih A, Ducray F, Sierra Del Rio M, Hoang-Xuan K, Delattre JY (2008) Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors. Oncologist 13:978-992
14. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P (2000) Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 482:193-199
15. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zauli G (2003) TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107:2250-2256
16. Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P (2003) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 92:732-740
17. Secchiero P, Gonelli A, Carnevale E, Corallini F, Rizzardi C, Zacchigna S, Melato M, Zauli G (2004) Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand. Neoplasia 6:364-373
18. Chen PL, Easton AS (2010) Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis. Biochem Biophys Res Commun 391:936-941
19. Cantarella G, Risuglia N, Dell'eva R, Lempereur L, Albini A, Pennisi G, Scoto GM, Noonan DN, Bernardini R (2006) TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br J Cancer 94:1428-1435
20. + cells. Angiogenesis 16:707-722
21. Lee SJ, Namkoong S, Kim YM, Kim CK, Lee H, Ha KS, Chung HT, Kwon YG, Kim YM (2006) Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways. Am J Physiol Heart Circ Physiol 291:H2836-H2846
22. Kim I, Moon SO, Koh KN, Kim H, Uhm CS, Kwak HJ, Kim NG, Koh GY (1999) Molecular cloning, expression, and characterization of angiopoietin-related protein. angiopoietin-related protein induces endothelial cell sprouting. J Biol Chem 274:26523-26528
23. Namkoong S, Chung BH, Ha KS, Lee H, Kwon YG, Kim YM (2008) Microscopic technique for the detection of nitric oxide-dependent angiogenesis in an animal model. Methods Enzymol 441:393-402
24. Lee SJ, Kim KM, Namkoong S, Kim CK, Kang YC, Lee H, Ha KS, Han JA, Chung HT, Kwon YG, Kim YM (2005) Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine. J Biol Chem 280:5781-5788
25. 2+ in TGF-β1-induced IL-6 expression. J Immunol 165:2190-2197
26. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671-674
27. Klagsbrun M (1991) Regulators of angiogenesis: stimulators, inhibitors, and extracellular matrix. J Cell Biochem 47:199-200
28. 2+ entry and endothelial tube formation. Circ Res 108:1190-1198
29. Rousseau S, Houle F, Kotanides H, Witte L, Waltenberger J, Landry J, Huot J (2000) Vascular endothelial growth factor (VEGF)-driven actin-based motility is mediated by VEGFR2 and requires concerted activation of stress-activated protein kinase 2 (SAPK2/p38) and geldanamycin-sensitive phosphorylation of focal adhesion kinase. J Biol Chem 275:10661-10672
30. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195
31. Maelfait J, Beyaert R (2008) Non-apoptotic functions of caspase-8. Biochem Pharmacol 76:1365-1373
32. Tavora B, Batista S, Reynolds LE, Jadeja S, Robinson S, Kostourou V, Hart I, Fruttiger M, Parsons M, Hodivala-Dilke KM (2010) Endothelial FAK is required for tumour angiogenesis. EMBO Mol Med 2:516-528
33. Gervais FG, Thornberry NA, Ruffolo SC, Nicholson DW, Roy S (1998) Caspases cleave focal adhesion kinase during apoptosis to generate a FRNK-like polypeptide. J Biol Chem 273:17102-17108
34. Ganapathy S, Chen Q, Singh KP, Shankar S, Srivastava RK (2010) Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS ONE 5:e15627
35. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factorrelated apoptosis-inducing ligand. Nat Med 6:564-567
36. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383-385
37. Martin JL, Charboneau R, Barke RA, Roy S (2010) Chronic morphine treatment inhibits LPS-induced angiogenesis: implications in wound healing. Cell Immunol 265:139-145
38. Kang YC, Kim KM, Lee KS, Namkoong S, Lee SJ, Han JA, Jeoung D, Ha KS, Kwon YG, Kim YM (2004) Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation. Cell Death Differ 11:1287-1298
39. Han SH, Kim M, Park K, Kim TH, Seol DW (2008) Blockade of processing/activation of caspase-3 by hypoxia. Biochem Biophys Res Commun 375:684-788
40. Raleigh JA, Calkins-Adams DP, Rinker LH, Ballenger CA, Weissler MC, Fowler WC Jr, Novotny DB, Varia MA (1998) Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res 58:3765-3768
41. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P (2000) Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 482:193-199
42. Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL, Rebrikov D, Brodianski VM, Kemper OC, Kollet O, Lapidot T, Soffer D, Sobe T, Avraham KB, Goncharov T, Holtmann H, Lonai P, Wallach D (1998) Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9:267-276
43. Sakamaki K, Inoue T, Asano M, Sudo K, Kazama H, Sakagami J, Sakata S, Ozaki M, Nakamura S, Toyokuni S, Osumi N, Iwakura Y, Yonehara S (2002) Ex vivo whole-embryo culture of caspase-8-deficient embryos normalize their aberrant phenotypes in the developing neural tube and heart. Cell Death Differ 9:1196-1206
44. Scharner D, Rössig L, Carmona G, Chavakis E, Urbich C, Fischer A, Kang TB, Wallach D, Chiang YJ, Deribe YL, Dikic I, Zeiher AM, Dimmeler S (2009) Caspase-8 is involved in neovascularization-promoting progenitor cell functions. Arterioscler Thromb Vasc Biol 29:571-578
45. Finlay D, Howes A, Vuori K (2009) Critical role for caspase-8 in epidermal growth factor signaling. Cancer Res 69:5023-5029
46. When LP, Fahrni JA, Troie S, Guan JL, Orth K, Rosen GD (1997) Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem 272:26056-26061
47. Kornberg LJ, Shaw LC, Spoerri PE, Caballero S, Grant MB (2004) Focal adhesion kinase overexpression induces enhanced pathological retinal angiogenesis. Invest Ophthalmol Vis Sci 45:4463-4469
48. Zhao Y, Sui X, Ren H (2010) From procaspase-8 to caspase-8: revising structural functions of caspase-8. J Cell Physiol 225:316-320
49. Finlay D, Vuori K (2007) Novel noncatalytic role for caspase-8 in promoting SEC-mediated adhesion and Erk signaling in neurobalstoma cells. Cancer Res 67:11704-11711
50. Cursi S, Rufini A, Stagni V, Condò I, Matafora V, Bachi A, Bonifazi AP, Coppola L, Superti-Furga G, Testi R, Barilà D (2006) Src kinase phosphorylates caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J 25:1895-1905
51. Senft J, Helfer B, Frisch SM (2007) Caspase-8 interacts with the p85 subunit of phosphatidylinositol 3-kinase to regulate cell adhesion and motility. Cancer Res 67:11505-11509
52. Barbero S, Barilà D, Mielgo A, Stagni V, Clair K, Stupack D (2008) Identification of a critical tyrosine residue in caspase 8 that promotes cell migration. J Biol Chem 283:13031-13034
53. Engelman JS (2009) Targeting PI3K signing in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550-562
54. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400
55. Shojaei F (2012) Anti-angiogenesis therapy in cancer: current challenges and further perspectives. Cancer Lett 320:130-137